Drug Trial Radar · NCT03768960
A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent
Last checked: Nov 20, 2026Latest source record: Feb 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Actual
Start
Jun 10, 2019
Primary completion
Jul 16, 2022
Study completion Jul 16, 2022
Sponsor
- Lead sponsor
- Johnson & Johnson Private LimitedJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Dec 7, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate the safety profile of daratumumab in routine clinical practice when given as monotherapy in Indian participants with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent.
Conditions
- Multiple Myeloma
Interventions
DaratumumabDrug
Participants will receive 16 mg/kg of daratumumab as IV infusion QW in Cycles 1 and 2 (Days 1, 8, 15 and 22) and Q2W in Cycle 3 to 6 (Days 1 and 15).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment Emergent Adverse Events (TEAE)Time frame: Approximately up to 29 weeks
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Avron Hospitals Pvt. Ltd
Ahmedabad, India
M S Ramaiah Medical College and Hospital
Bengaluru, India
Apollo Hospitals
Bhubaneswar, India
Sparsh Hospitals & Critical Care (Pvt) Ltd
Bhubaneswar, India
Post Graduate Institute of Medical Education And Research PGIMER
Chandigarh, India
Apollo Hospitals
Hyderabad, India
Basavatarakam Indo-American Hospital
Hyderabad, India
Cytecare Hospitals Pvt. Ltd
Karnataka, India
Tata Medical Center
Kolkata, India
Shatabdi Super Speciality Hospital
Mumbai Naka, India
Kingsway Hospital
Nagpur, India
Apex Wellness Hospital
Nashik, India
All India Institute of Medical Sciences
New Delhi, India
Jawaharlal Institute of Postgraduate Medical Education and Research
Puducherry, India
Deenanath Mangeshkar Hospital and Research Centre
Pune, India
Noble Hospital Pvt Ltd
Pune, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.